Refractory Secondary Acute Myeloid Leukemia Clinical Trials in Columbus, Ohio

Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia